CN101014580B - 吗啉化合物 - Google Patents
吗啉化合物 Download PDFInfo
- Publication number
- CN101014580B CN101014580B CN2005800301370A CN200580030137A CN101014580B CN 101014580 B CN101014580 B CN 101014580B CN 2005800301370 A CN2005800301370 A CN 2005800301370A CN 200580030137 A CN200580030137 A CN 200580030137A CN 101014580 B CN101014580 B CN 101014580B
- Authority
- CN
- China
- Prior art keywords
- methyl
- morpholin
- acetamide
- ylthio
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC(NCC1OCCN(CC2(*)CCCCC2)C1)=O Chemical compound CC(NCC1OCCN(CC2(*)CCCCC2)C1)=O 0.000 description 5
- LPHPYCBTYVSMTC-UHFFFAOYSA-N CC(C(CN1CC(C[NH+](CCSc2nnc(SC(C)(C)C(O)O)[s]2)[O-])OCC1)C=C1Cl)C=C1Cl Chemical compound CC(C(CN1CC(C[NH+](CCSc2nnc(SC(C)(C)C(O)O)[s]2)[O-])OCC1)C=C1Cl)C=C1Cl LPHPYCBTYVSMTC-UHFFFAOYSA-N 0.000 description 1
- MMUORFBEAQPGFE-INIZCTEOSA-N CC(N(C)N1)=CC=C1SCC(NC[C@@H]1OCCN(Cc(cc2Cl)ccc2Cl)C1)=O Chemical compound CC(N(C)N1)=CC=C1SCC(NC[C@@H]1OCCN(Cc(cc2Cl)ccc2Cl)C1)=O MMUORFBEAQPGFE-INIZCTEOSA-N 0.000 description 1
- NUKNSYDJEJVZLD-HNNXBMFYSA-N CC(c1c(C)nc(SCC(NC[C@@H]2OCCN(Cc(cc3Cl)ccc3Cl)C2)=O)[s]1)=O Chemical compound CC(c1c(C)nc(SCC(NC[C@@H]2OCCN(Cc(cc3Cl)ccc3Cl)C2)=O)[s]1)=O NUKNSYDJEJVZLD-HNNXBMFYSA-N 0.000 description 1
- MRWWLSVHOWSLKF-UHFFFAOYSA-N CC1(Nc2cccc(C(N3)=CSC3(C)SCC(NCC3OCCN(Cc(cc4Cl)ccc4Cl)C3)=O)c2)OC1 Chemical compound CC1(Nc2cccc(C(N3)=CSC3(C)SCC(NCC3OCCN(Cc(cc4Cl)ccc4Cl)C3)=O)c2)OC1 MRWWLSVHOWSLKF-UHFFFAOYSA-N 0.000 description 1
- HLXVVRFMVRTPPG-UHFFFAOYSA-N CC1SC(SCC(NCC2OCCN(CC(C3)=CC=C(C)C3(C)Cl)C2)=O)=NC1c(cc1)ccc1C(O)=O Chemical compound CC1SC(SCC(NCC2OCCN(CC(C3)=CC=C(C)C3(C)Cl)C2)=O)=NC1c(cc1)ccc1C(O)=O HLXVVRFMVRTPPG-UHFFFAOYSA-N 0.000 description 1
- MFQFGLVRWOLQLF-UHFFFAOYSA-N CCOC(Cc(cc1)ccc1SCC(NCC1OCCN(Cc(cc2Cl)ccc2Cl)C1)=O)=O Chemical compound CCOC(Cc(cc1)ccc1SCC(NCC1OCCN(Cc(cc2Cl)ccc2Cl)C1)=O)=O MFQFGLVRWOLQLF-UHFFFAOYSA-N 0.000 description 1
- PTOCVHGTOHMZRV-UHFFFAOYSA-N CN(C(C=C1)=O)N=C1SCC(NCC1OCCN(Cc(cc2)cc(Cl)c2Cl)C1)=O Chemical compound CN(C(C=C1)=O)N=C1SCC(NCC1OCCN(Cc(cc2)cc(Cl)c2Cl)C1)=O PTOCVHGTOHMZRV-UHFFFAOYSA-N 0.000 description 1
- XVQYNZNARAYGOH-UHFFFAOYSA-N Cc1c(C(O)=O)nc(SCC(NCC2OCCN(Cc3ccc(C)c(C)c3)C2)=O)[s]1 Chemical compound Cc1c(C(O)=O)nc(SCC(NCC2OCCN(Cc3ccc(C)c(C)c3)C2)=O)[s]1 XVQYNZNARAYGOH-UHFFFAOYSA-N 0.000 description 1
- WAOSWOZFVUPGFW-UHFFFAOYSA-N Cc1nnc(SCC(NCC2OCCN(Cc(cc3Cl)ccc3Cl)C2)=O)[s]1 Chemical compound Cc1nnc(SCC(NCC2OCCN(Cc(cc3Cl)ccc3Cl)C2)=O)[s]1 WAOSWOZFVUPGFW-UHFFFAOYSA-N 0.000 description 1
- BHXRCTFSWAJAFY-UHFFFAOYSA-N N=Nc1nnc(SCC(NCC2OCCN(Cc3cccc(Cl)c3)C2)=O)[s]1 Chemical compound N=Nc1nnc(SCC(NCC2OCCN(Cc3cccc(Cl)c3)C2)=O)[s]1 BHXRCTFSWAJAFY-UHFFFAOYSA-N 0.000 description 1
- TZGYOLZUKJXONH-BBRMVZONSA-N NC(C[C@@H](C(O)=O)NC(c1c[s]c(SCC(NC[C@@H]2OCCN(Cc(cc3)cc(Cl)c3Cl)C2)=O)n1)=O)=O Chemical compound NC(C[C@@H](C(O)=O)NC(c1c[s]c(SCC(NC[C@@H]2OCCN(Cc(cc3)cc(Cl)c3Cl)C2)=O)n1)=O)=O TZGYOLZUKJXONH-BBRMVZONSA-N 0.000 description 1
- OQTFGHKIDLRXAC-UHFFFAOYSA-N NC(Cc1c[s]c(SCC(NCC2OCCN(Cc3ccc(cc(cc4)F)c4c3)C2)=O)n1)=O Chemical compound NC(Cc1c[s]c(SCC(NCC2OCCN(Cc3ccc(cc(cc4)F)c4c3)C2)=O)n1)=O OQTFGHKIDLRXAC-UHFFFAOYSA-N 0.000 description 1
- KXBQBBQMLIGNGV-HNNXBMFYSA-N NC(Cc1c[s]c(SCC(NC[C@@H]2OCCN(Cc(c(Cl)c3)ccc3Cl)C2)=O)n1)=O Chemical compound NC(Cc1c[s]c(SCC(NC[C@@H]2OCCN(Cc(c(Cl)c3)ccc3Cl)C2)=O)n1)=O KXBQBBQMLIGNGV-HNNXBMFYSA-N 0.000 description 1
- HXAOAFBSDWUWQS-UHFFFAOYSA-N Nc1ccc(CCc2c-3nc(SCC(NCC4OCCN(Cc(cc5Cl)ccc5Cl)C4)=O)[s]2)c-3c1 Chemical compound Nc1ccc(CCc2c-3nc(SCC(NCC4OCCN(Cc(cc5Cl)ccc5Cl)C4)=O)[s]2)c-3c1 HXAOAFBSDWUWQS-UHFFFAOYSA-N 0.000 description 1
- PCUJUMBJDHBDHI-UHFFFAOYSA-N OC(c(cc1)ccc1SCC(NCC1OCCN(Cc(cc2Cl)ccc2F)C1)=O)=O Chemical compound OC(c(cc1)ccc1SCC(NCC1OCCN(Cc(cc2Cl)ccc2F)C1)=O)=O PCUJUMBJDHBDHI-UHFFFAOYSA-N 0.000 description 1
- JZBBYFNUJTUOBH-UHFFFAOYSA-N OS(CCCC(NCC1OCCN(Cc2cccc(Cl)c2)C1)=O)=O Chemical compound OS(CCCC(NCC1OCCN(Cc2cccc(Cl)c2)C1)=O)=O JZBBYFNUJTUOBH-UHFFFAOYSA-N 0.000 description 1
- ZOKNXPMUEHPEDZ-UHFFFAOYSA-N b1c2cccc1C2 Chemical compound b1c2cccc1C2 ZOKNXPMUEHPEDZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004261655 | 2004-09-08 | ||
| JP261655/2004 | 2004-09-08 | ||
| PCT/JP2005/017002 WO2006028284A1 (ja) | 2004-09-08 | 2005-09-08 | モルホリン化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101014580A CN101014580A (zh) | 2007-08-08 |
| CN101014580B true CN101014580B (zh) | 2011-05-04 |
Family
ID=36036551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005800301370A Expired - Fee Related CN101014580B (zh) | 2004-09-08 | 2005-09-08 | 吗啉化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7935700B2 (enExample) |
| EP (1) | EP1801108B9 (enExample) |
| JP (1) | JP4970946B2 (enExample) |
| KR (1) | KR101011848B1 (enExample) |
| CN (1) | CN101014580B (enExample) |
| CA (1) | CA2579207C (enExample) |
| DK (1) | DK1801108T3 (enExample) |
| ES (1) | ES2396419T3 (enExample) |
| IN (1) | IN2014CN03493A (enExample) |
| PL (1) | PL1801108T3 (enExample) |
| PT (1) | PT1801108E (enExample) |
| TW (1) | TW200619212A (enExample) |
| WO (1) | WO2006028284A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE398616T1 (de) * | 2005-02-04 | 2008-07-15 | Ctg Pharma S R L | Neue 4-aminochinolinderivate als antimalariamittel |
| RS52711B (sr) | 2005-05-10 | 2013-08-30 | Incyte Corporation | Modulatori indolamin 2,3-dioksigenaze i postupci upotrebe istih |
| EP1971583B1 (en) | 2005-12-20 | 2015-03-25 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US8030303B2 (en) | 2006-07-11 | 2011-10-04 | Mitsubishi Tanabe Pharma Corporation | Salt of morpholine compound |
| WO2008036642A2 (en) * | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) * | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| US20080146624A1 (en) * | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| WO2008058178A1 (en) * | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| JP5313881B2 (ja) | 2007-04-04 | 2013-10-09 | 興和株式会社 | テトラヒドロイソキノリン化合物 |
| PL2315756T3 (pl) | 2008-07-08 | 2015-02-27 | Incyte Holdings Corp | 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy |
| US10130634B2 (en) | 2013-07-24 | 2018-11-20 | Mitsubishi Tanabe Pharma Corporation | Therapeutic agent for ophthalmic disease |
| KR102617531B1 (ko) | 2013-11-08 | 2023-12-27 | 인사이트 홀딩스 코포레이션 | 인돌아민 2,3-디옥시게나제 억제제의 합성 방법 |
| WO2020203822A1 (ja) * | 2019-03-29 | 2020-10-08 | 千寿製薬株式会社 | 血管新生を伴う網膜疾患の治療又は予防のための併用医薬 |
| US12472166B2 (en) | 2019-08-26 | 2025-11-18 | Stichting Vumc | Inhibition of mycobacterial type VII secretion |
| EP4076448A4 (en) | 2019-12-20 | 2024-03-27 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| US20230312697A1 (en) | 2020-06-11 | 2023-10-05 | Alkahest Inc. | Methods of improving retina-associated disease outcome using ccr3-inhibitors |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002026722A1 (en) * | 2000-09-29 | 2002-04-04 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| WO2004004731A1 (en) * | 2002-07-02 | 2004-01-15 | F. Hoffmann-La Roche Ag | 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63264467A (ja) | 1986-04-30 | 1988-11-01 | Dainippon Pharmaceut Co Ltd | ベンズアミド誘導体 |
| US4870074A (en) * | 1986-04-30 | 1989-09-26 | Dainippon Pharmaceutical Co., Ltd. | Substituted benzamide derivatives, for enhancing gastrointestinal motility |
| JPH03148276A (ja) * | 1989-11-01 | 1991-06-25 | Yoshitomi Pharmaceut Ind Ltd | 光学活性なピリドンカルボン酸化合物 |
| WO1997024325A1 (en) | 1995-12-28 | 1997-07-10 | Takeda Chemical Industries, Ltd. | DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS |
| EP0920306A2 (en) | 1996-07-12 | 1999-06-09 | Leukosite, Inc. | Chemokine receptor antagonists and methods of use therefor |
| AU3633997A (en) | 1996-07-29 | 1998-02-20 | Banyu Pharmaceutical Co., Ltd. | Chemokine receptor antagonists |
| WO1998025617A1 (en) | 1996-12-13 | 1998-06-18 | Merck & Co., Inc. | Substituted aryl piperazines as modulators of chemokine receptor activity |
| CA2329821A1 (en) | 1998-04-27 | 1999-11-04 | Dashyant Dhanak | Ccr-3 receptor antagonists |
| EP1076557A1 (en) | 1998-04-27 | 2001-02-21 | Smithkline Beecham Corporation | Ccr-3 receptor antagonists |
| WO2000031033A1 (en) | 1998-11-20 | 2000-06-02 | F. Hoffmann-La Roche Ag | Piperidine ccr-3 receptor antagonists |
| CA2319435A1 (en) | 1998-12-04 | 2000-06-15 | Toray Industries, Inc. | Triazolo derivatives and chemokine inhibitors containing the same as effective component |
| AU2942000A (en) * | 1999-03-11 | 2000-09-28 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivatives |
| KR20010108394A (ko) | 1999-03-26 | 2001-12-07 | 다비드 에 질레스 | 신규 화합물 |
| SE9902987D0 (sv) | 1999-08-24 | 1999-08-24 | Astra Pharma Prod | Novel compounds |
| AU2001280187A1 (en) | 2000-08-28 | 2002-03-13 | Toray Industries, Inc. | Cyclic amine derivatives |
| CA2423305A1 (en) | 2000-09-29 | 2002-04-04 | Glaxo Group Limited | Compounds useful in the treatment of inflammatory diseases |
| GB0104050D0 (en) | 2001-02-19 | 2001-04-04 | Astrazeneca Ab | Chemical compounds |
| WO2002088111A1 (en) | 2001-04-27 | 2002-11-07 | Mitsubishi Pharma Corporation | Novel benzylpiperidine compound |
| GB0207445D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| TW200400035A (en) | 2002-03-28 | 2004-01-01 | Glaxo Group Ltd | Novel compounds |
| GB0207439D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0208158D0 (en) | 2002-03-28 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| GB0207443D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0207436D0 (en) | 2002-03-28 | 2002-05-08 | Glaxo Group Ltd | Novel compounds |
| GB0212357D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
| GB0212355D0 (en) | 2002-05-29 | 2002-07-10 | Glaxo Group Ltd | Novel compounds |
-
2005
- 2005-09-08 IN IN3493CHN2014 patent/IN2014CN03493A/en unknown
- 2005-09-08 EP EP05783689.2A patent/EP1801108B9/en not_active Expired - Lifetime
- 2005-09-08 KR KR1020077007863A patent/KR101011848B1/ko not_active Expired - Fee Related
- 2005-09-08 DK DK05783689.2T patent/DK1801108T3/da active
- 2005-09-08 US US11/662,228 patent/US7935700B2/en not_active Expired - Fee Related
- 2005-09-08 PL PL05783689T patent/PL1801108T3/pl unknown
- 2005-09-08 PT PT57836892T patent/PT1801108E/pt unknown
- 2005-09-08 JP JP2006535186A patent/JP4970946B2/ja not_active Expired - Fee Related
- 2005-09-08 CN CN2005800301370A patent/CN101014580B/zh not_active Expired - Fee Related
- 2005-09-08 TW TW094130939A patent/TW200619212A/zh not_active IP Right Cessation
- 2005-09-08 CA CA2579207A patent/CA2579207C/en not_active Expired - Fee Related
- 2005-09-08 ES ES05783689T patent/ES2396419T3/es not_active Expired - Lifetime
- 2005-09-08 WO PCT/JP2005/017002 patent/WO2006028284A1/ja not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002026722A1 (en) * | 2000-09-29 | 2002-04-04 | Glaxo Group Limited | Morpholin-acetamide derivatives for the treatment of inflammatory diseases |
| WO2004004731A1 (en) * | 2002-07-02 | 2004-01-15 | F. Hoffmann-La Roche Ag | 2, 5-substituted pyrimidine derivatives as ccr-3 receptor antagonists ix |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101011848B1 (ko) | 2011-02-01 |
| PT1801108E (pt) | 2012-12-03 |
| CN101014580A (zh) | 2007-08-08 |
| JP4970946B2 (ja) | 2012-07-11 |
| KR20070099528A (ko) | 2007-10-09 |
| DK1801108T3 (da) | 2013-02-18 |
| EP1801108B9 (en) | 2013-11-20 |
| US7935700B2 (en) | 2011-05-03 |
| WO2006028284A1 (ja) | 2006-03-16 |
| TW200619212A (en) | 2006-06-16 |
| TWI367209B (enExample) | 2012-07-01 |
| CA2579207C (en) | 2011-10-18 |
| EP1801108A4 (en) | 2010-10-13 |
| EP1801108B1 (en) | 2012-11-14 |
| EP1801108A1 (en) | 2007-06-27 |
| JPWO2006028284A1 (ja) | 2008-05-08 |
| PL1801108T3 (pl) | 2013-04-30 |
| US20070265257A1 (en) | 2007-11-15 |
| ES2396419T3 (es) | 2013-02-21 |
| IN2014CN03493A (enExample) | 2015-07-03 |
| CA2579207A1 (en) | 2006-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101014580B (zh) | 吗啉化合物 | |
| JP4261914B2 (ja) | 新規ベンジルピペリジン化合物 | |
| CN108884029B (zh) | Lsd1抑制剂 | |
| KR101321728B1 (ko) | １１-베타-하이드록시스테로이드 데하이드로게나아제 타입 １ 효소의 억제제로서의 아다만틸-아세트아미드 유도체 | |
| CN112996529B (zh) | Matriptase 2抑制剂及其用途 | |
| CA3118094A1 (en) | Amide-substituted heterocyclic compounds for the treatment of conditions related to the modulation of il-12, il-23 and/or ifn-alpha | |
| US20030069169A1 (en) | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders | |
| CN112218859A (zh) | 蛋白水解调节剂及相关使用方法 | |
| TW202332674A (zh) | Tlr7/8拮抗劑及其用途 | |
| KR20020067050A (ko) | 염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제 | |
| WO2003099286A1 (en) | Pyrrolotriazinone compounds and their use to treat diseases | |
| MX2014009281A (es) | Prolinas/piperidinas sustituidas como antagonistas del receptor de orexina. | |
| JP2021522253A (ja) | 化合物及びその使用 | |
| WO2004037817A1 (ja) | Ｎ−オキシド化合物 | |
| CN114466844A (zh) | N-(1h-咪唑-2-基)苯甲酰胺化合物及包含其作为活性成分的药物组合物 | |
| CN106854207A (zh) | 呔嗪类衍生物、其制备方法、药物组合物和用途 | |
| IL269379B (en) | cxcr4 receptor modulators and related uses | |
| JP2023552655A (ja) | ボロン酸化合物 | |
| JP2005097276A (ja) | 縮合ピリミジン誘導体およびその用途 | |
| ES2366114T3 (es) | Derivados de 3,4-dihalobencilpiperidina y su uso médico. | |
| AU2002245601A1 (en) | Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: TANABE MITSUBISHI PHARMACEUTICAL CO. Free format text: FORMER OWNER: MITSUBISHI PHARMACEUTICAL CORP. Effective date: 20081024 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20081024 Address after: Japan Osaka Applicant after: MITSUBISHI TANABE PHARMA Corp. Address before: Japan Osaka Applicant before: MITSUBISHI PHARMA Corp. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110504 Termination date: 20210908 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |